WO2007092620A3 - Stable formulations, and methods of their preparation and use - Google Patents

Stable formulations, and methods of their preparation and use Download PDF

Info

Publication number
WO2007092620A3
WO2007092620A3 PCT/US2007/003573 US2007003573W WO2007092620A3 WO 2007092620 A3 WO2007092620 A3 WO 2007092620A3 US 2007003573 W US2007003573 W US 2007003573W WO 2007092620 A3 WO2007092620 A3 WO 2007092620A3
Authority
WO
WIPO (PCT)
Prior art keywords
methods
formulations
preparation
stable formulations
rapamycin
Prior art date
Application number
PCT/US2007/003573
Other languages
French (fr)
Other versions
WO2007092620A2 (en
Inventor
Sreenivasu Mudumba
Thierry Nivaggioli
Sudeep Kaur Takhar
Original Assignee
Macusight Inc
Sreenivasu Mudumba
Thierry Nivaggioli
Sudeep Kaur Takhar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Macusight Inc, Sreenivasu Mudumba, Thierry Nivaggioli, Sudeep Kaur Takhar filed Critical Macusight Inc
Priority to CA2635797A priority Critical patent/CA2635797C/en
Priority to EP07763361A priority patent/EP2001438A2/en
Priority to AU2007212271A priority patent/AU2007212271B2/en
Priority to BRPI0707612A priority patent/BRPI0707612B8/en
Priority to CN2007800049514A priority patent/CN101605529B/en
Priority to JP2008554395A priority patent/JP5528708B2/en
Priority to KR1020147020142A priority patent/KR20140093764A/en
Publication of WO2007092620A2 publication Critical patent/WO2007092620A2/en
Priority to KR1020087021928A priority patent/KR101478164B1/en
Publication of WO2007092620A3 publication Critical patent/WO2007092620A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/436—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having oxygen as a ring hetero atom, e.g. rapamycin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/14—Decongestants or antiallergics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01F—MIXING, e.g. DISSOLVING, EMULSIFYING OR DISPERSING
    • B01F33/00—Other mixers; Mixing plants; Combinations of mixers
    • B01F33/40—Mixers using gas or liquid agitation, e.g. with air supply tubes

Abstract

Described herein are formulations comprising therapeutic agents, including but not limited to formulations comprising rapamycin, pharmaceutical formulations, unit dose forms, kits, methods of preparing formulations, and methods of using formulations. Such formulations and methods have increased stability.
PCT/US2007/003573 2006-02-09 2007-02-09 Stable formulations, and methods of their preparation and use WO2007092620A2 (en)

Priority Applications (8)

Application Number Priority Date Filing Date Title
CA2635797A CA2635797C (en) 2006-02-09 2007-02-09 Stable formulations, and methods of their preparation and use
EP07763361A EP2001438A2 (en) 2006-02-09 2007-02-09 Stable formulations, and methods of their preparation and use
AU2007212271A AU2007212271B2 (en) 2006-02-09 2007-02-09 Stable formulations, and methods of their preparation and use
BRPI0707612A BRPI0707612B8 (en) 2006-02-09 2007-02-09 sealed vessel and liquid formulations contained therein
CN2007800049514A CN101605529B (en) 2006-02-09 2007-02-09 Stable formulations, and methods of their preparation and use
JP2008554395A JP5528708B2 (en) 2006-02-09 2007-02-09 Stable formulations and methods for preparing and using them
KR1020147020142A KR20140093764A (en) 2006-02-09 2007-02-09 Stable formulations, and methods of their preparation and use
KR1020087021928A KR101478164B1 (en) 2006-02-09 2008-09-08 Stable formulations and methods of their preparation and use

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77201806P 2006-02-09 2006-02-09
US60/772,018 2006-02-09

Publications (2)

Publication Number Publication Date
WO2007092620A2 WO2007092620A2 (en) 2007-08-16
WO2007092620A3 true WO2007092620A3 (en) 2009-03-26

Family

ID=38261629

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/003573 WO2007092620A2 (en) 2006-02-09 2007-02-09 Stable formulations, and methods of their preparation and use

Country Status (9)

Country Link
US (2) US8492400B2 (en)
EP (1) EP2001438A2 (en)
JP (1) JP5528708B2 (en)
KR (2) KR20140093764A (en)
CN (1) CN101605529B (en)
AU (1) AU2007212271B2 (en)
BR (1) BRPI0707612B8 (en)
CA (1) CA2635797C (en)
WO (1) WO2007092620A2 (en)

Families Citing this family (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8673341B2 (en) * 2004-04-30 2014-03-18 Allergan, Inc. Intraocular pressure reduction with intracameral bimatoprost implants
US9498457B2 (en) 2004-04-30 2016-11-22 Allergan, Inc. Hypotensive prostamide-containing biodegradable intraocular implants and related implants
US8722097B2 (en) 2004-04-30 2014-05-13 Allergan, Inc. Oil-in-water method for making polymeric implants containing a hypotensive lipid
US8663639B2 (en) 2005-02-09 2014-03-04 Santen Pharmaceutical Co., Ltd. Formulations for treating ocular diseases and conditions
DK1848431T3 (en) 2005-02-09 2016-04-18 Santen Pharmaceutical Co Ltd LIQUID FORMULATIONS FOR TREATMENT OF DISEASES OR CONDITIONS
JP2008533204A (en) * 2005-03-21 2008-08-21 マクサイト， インコーポレイテッド Drug delivery system for treatment of disease or condition
JP4358785B2 (en) * 2005-05-27 2009-11-04 麒麟麦酒株式会社 Method for measuring oxygen content in sealed container and piercing device for sealed container used therefor
JP5528708B2 (en) 2006-02-09 2014-06-25 参天製薬株式会社 Stable formulations and methods for preparing and using them
CN101443004B (en) 2006-03-23 2013-03-06 参天制药株式会社 Formulations and methods for vascular permeability-related diseases or conditions
US9386770B2 (en) * 2006-06-13 2016-07-12 Phibro Animal Health Corp. Use of predissolved pristinamycin-type and polyether ionophore type antimicrobial agents in the production of ethanol
WO2009018333A2 (en) * 2007-07-30 2009-02-05 Board Of Supervisors Of Louisiana State University And Agricultural And Mechanical College Dha and pedf, a therapeutic composition for nerve and retinal pigment epithelial cells
ES2584904T3 (en) * 2007-09-10 2016-09-30 Boston Biomedical, Inc. New compositions and methods for cancer treatment
KR20100072333A (en) * 2007-11-01 2010-06-30 보오슈 앤드 롬 인코포레이팃드 Non-aqueous water-miscible materials as vehicles for drug delivery
MX2010012080A (en) * 2008-05-05 2011-04-11 Univ Winthrop Hospital Method for improving cardiovascular risk profile of cox inhibitors.
WO2010006306A1 (en) * 2008-07-10 2010-01-14 Inspire Pharmaceuticals, Inc. Method of treating blepharitis
CN102231969A (en) * 2008-10-03 2011-11-02 万能医药公司 Macrocyclic lactone compounds and methods for their use
WO2010085572A1 (en) * 2009-01-23 2010-07-29 Inspire Pharmaceuticals, Inc. Method of treating dry eye disease with azithromycin
US20110305747A1 (en) * 2009-07-30 2011-12-15 Allergan, Inc. Combination of dapsone with other anti-acne agents
TWI492769B (en) 2009-09-23 2015-07-21 Alcon Res Ltd Injectable aqueous ophthalmic composition and method of use therefor
EP2394636B1 (en) * 2010-05-28 2014-03-19 Novagali Pharma S.A. Method for treating retinal conditions using an intraocular tamponade
EP2361636A1 (en) * 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
TW201138782A (en) * 2010-04-26 2011-11-16 Besins Healthcare Lu Sarl Low-oil pharmaceutical emulsion compositions comprising progestogen
AU2011260016B2 (en) * 2010-06-02 2013-08-22 Fresenius Kabi Oncology Ltd. Stable pharmaceutical compositions of Rapamycin esters
CA2814805C (en) 2010-10-21 2021-11-02 Rtu Pharmaceuticals, Llc Ready to use ketorolac formulations
US9504664B2 (en) 2010-10-29 2016-11-29 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8895537B2 (en) 2010-10-29 2014-11-25 Infirst Healthcare Ltd. Compositions and methods for treating cardiovascular diseases
US10695432B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US11224659B2 (en) 2010-10-29 2022-01-18 Infirst Healthcare Limited Solid solution compositions and use in severe pain
US9308213B2 (en) 2010-10-29 2016-04-12 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US10695431B2 (en) 2010-10-29 2020-06-30 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9271950B2 (en) 2010-10-29 2016-03-01 Infirst Healthcare Limited Compositions for treating chronic inflammation and inflammatory diseases
US9744132B2 (en) 2010-10-29 2017-08-29 Infirst Healthcare Limited Solid solution compositions and use in chronic inflammation
US11202831B2 (en) 2010-10-29 2021-12-21 Infirst Healthcare Limited Solid solution compositions and use in cardiovascular disease
US9737500B2 (en) 2010-10-29 2017-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US11730709B2 (en) 2010-10-29 2023-08-22 Infirst Healthcare Limited Compositions and methods for treating severe pain
US8349005B2 (en) 2011-01-03 2013-01-08 Masatoshi Murata Method for burying implant to choroid
US20120219682A1 (en) * 2011-02-28 2012-08-30 Frank Monteleone Antimicrobial compositions within antioxidant solutions used to protect whole protein foods
DE102011108948A1 (en) * 2011-07-29 2013-01-31 Achim Göpferich Aqueous, colloidal solutions of lipophilic substances, in particular drug solutions
CN102319207A (en) * 2011-08-01 2012-01-18 福建省微生物研究所 42-(dimethylphosphinate) rapamycin liquid composition
US8912215B2 (en) 2011-12-13 2014-12-16 Everon Biosciences, Inc. Rapamycin composition
AU2013355043A1 (en) * 2012-12-06 2015-07-02 Tobira Therapeutics, Inc. Oligonucleotide formulation
JP6433085B2 (en) 2013-04-09 2018-12-05 ボストン バイオメディカル， インコーポレイテッド 2-acetylnaphtho [2,3-b] furan-4,9-dione for use in the treatment of cancer
PL3119794T3 (en) 2014-06-25 2018-04-30 NuCana plc Formulation comprising a gemcitabine-prodrug
HRP20230584T1 (en) 2014-06-25 2023-09-15 NuCana plc Gemcitabine prodrugs
GB201512728D0 (en) * 2015-07-20 2015-08-26 Isis Innovation Nanoencapsulated oxygen
GB201522764D0 (en) 2015-12-23 2016-02-03 Nucana Biomed Ltd Formulations of phosphate derivatives
US20170239250A1 (en) 2016-02-19 2017-08-24 Eagle Pharmaceuticals, Inc. Pemetrexed formulations
JP6944958B2 (en) 2016-05-25 2021-10-06 参天製薬株式会社 Use of sirolimus for the treatment of exudative age-related macular degeneration with persistent edema
CA2972296A1 (en) 2016-06-30 2017-12-30 Durect Corporation Depot formulations
US10682340B2 (en) 2016-06-30 2020-06-16 Durect Corporation Depot formulations
JP7106563B2 (en) 2016-11-29 2022-07-26 スミトモ ファーマ オンコロジー， インコーポレイテッド Naphthofuran derivatives, their preparation and methods of use
CA3049543A1 (en) * 2017-01-06 2018-07-12 Santen Pharmaceutical Co., Ltd. Intratumoral administration of sirolimus for treatment of prostate cancer
US11065217B2 (en) 2017-01-27 2021-07-20 Temple University—Of the Commonwealth System of Higher Education Use of short chain fatty acids for the treatment and prevention of diseases and disorders
JP6195028B1 (en) * 2017-02-02 2017-09-13 セントラル硝子株式会社 Method for preserving α, α-difluoroacetaldehyde alkyl hemiacetal
US11285081B2 (en) 2017-02-17 2022-03-29 Santen Pharmaceutical Co., Ltd. Sealed preparation container and use for same
CA3062656A1 (en) 2017-05-17 2018-11-22 Boston Biomedical, Inc. Methods for treating cancer
CN107334734B (en) * 2017-07-10 2020-03-17 浙江大学 Ophthalmic preparation of sirolimus or derivatives thereof
US10532221B2 (en) * 2017-08-17 2020-01-14 Justin C. Quon Method of noninvasive treatment of diabetic retinopathy
EP3691654A4 (en) 2017-09-25 2021-11-24 Surface Pharmaceuticals, Inc. Ophthalmic pharmaceutical compositions and methods for treating ocular surface disease
US20210213045A1 (en) * 2017-11-20 2021-07-15 Veloce Biopharma Llc Novel ophthalmic composition and methods of use
MX2020006425A (en) * 2017-12-21 2023-01-12 Siemens Healthcare Diagnostics Inc Compositions comprising stabilized oxygen and methods of forming the same.
WO2019135779A1 (en) * 2018-01-08 2019-07-11 Veloce Biopharma, Llc Novel ophthalmic composition and methods of use
CN111712231A (en) * 2018-02-23 2020-09-25 百多力股份公司 Parenteral formulation materials and methods for 40-O-cyclic hydrocarbon esters and related structures
EA202092974A1 (en) * 2018-06-01 2021-04-09 Байер Кропсайенс Лп STABILIZED FUNGICIDE COMPOSITION CONTAINING CYCLODEXTRIN
KR102351951B1 (en) * 2020-05-06 2022-01-17 한국원자력연구원 Method for detecting mycobacterium tuberculosis

Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2382240A1 (en) * 1977-03-03 1978-09-29 Mouls Pierre Ophthalmic solution diffusion equipment - delivers fine mist to cornea indirectly using cup with baffles
WO2000006121A1 (en) * 1998-07-24 2000-02-10 Jago Research Ag Medicinal aerosol formulations
WO2000033878A2 (en) * 1998-12-07 2000-06-15 Novartis Ag Stabilization of macrolides
WO2001028522A2 (en) * 1999-10-18 2001-04-26 Fujisawa Pharmaceutical Co., Ltd. Method for producing liposome preparation
WO2001093830A1 (en) * 2000-06-06 2001-12-13 Pharmatop Scr Method for obtaining aqueous formulations of oxidation-sensitive active principles
JP2002332225A (en) * 2001-05-09 2002-11-22 Lion Corp Ophthalmic composition
WO2004011000A1 (en) * 2002-07-30 2004-02-05 Wyeth Parenteral formulations containing a rapamycin hydroxyester
WO2006026531A1 (en) * 2004-08-27 2006-03-09 Cordis Corporation Solvent free amorphous rapamycin
WO2006086750A1 (en) * 2005-02-09 2006-08-17 Macusight, Inc. Liquid formulations for treatment of diseases or conditions
WO2007065588A1 (en) * 2005-12-06 2007-06-14 Pari Pharma Gmbh Pharmaceutical compositions comprising cyclosporin
WO2007083316A2 (en) * 2006-01-23 2007-07-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Microspheres comprising nanocapsules containing a lipophilic drug

Family Cites Families (241)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3416530A (en) 1966-03-02 1968-12-17 Richard A. Ness Eyeball medication dispensing tablet
US3630200A (en) 1969-06-09 1971-12-28 Alza Corp Ocular insert
US3828777A (en) 1971-11-08 1974-08-13 Alza Corp Microporous ocular device
US3914402A (en) 1973-06-14 1975-10-21 Alza Corp Ophthalmic dosage form, for releasing medication over time
US3926188A (en) 1974-11-14 1975-12-16 Alza Corp Laminated drug dispenser
US4093709A (en) 1975-01-28 1978-06-06 Alza Corporation Drug delivery devices manufactured from poly(orthoesters) and poly(orthocarbonates)
US4014335A (en) 1975-04-21 1977-03-29 Alza Corporation Ocular drug delivery device
US4300557A (en) 1980-01-07 1981-11-17 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for treating intraocular malignancies
AU543727B2 (en) 1980-06-02 1985-05-02 Ayerst Mckenna & Harrison Inc. Injectable composition of rapamycin
IT1141715B (en) 1980-06-06 1986-10-08 Sadepan Chimica Spa UREA-FORMALDEHYDE RESIN BASED ADHESIVE WITH CALCIUM AND / OR AMMONIUM LIGNINSULPHONATE, UREA FORMALDEHYDE RESIN MODIFIED WITH CALCIUM LIGNINSULPHONATE AND / OR AMMONIUM AND PRODUCTION METHOD OF THE SAME, FOR THE PREPARATION OF WOOD PANELS
US4316885A (en) 1980-08-25 1982-02-23 Ayerst, Mckenna And Harrison, Inc. Acyl derivatives of rapamycin
US4650803A (en) 1985-12-06 1987-03-17 University Of Kansas Prodrugs of rapamycin
US5322691A (en) 1986-10-02 1994-06-21 Sohrab Darougar Ocular insert with anchoring protrusions
US5147647A (en) 1986-10-02 1992-09-15 Sohrab Darougar Ocular insert for the fornix
KR920003601B1 (en) 1987-09-03 1992-05-04 유니버시티 어브 죠지아 리서취 화운데이션 인코포레이티드 Ocular cyclosporin composition
US4997652A (en) 1987-12-22 1991-03-05 Visionex Biodegradable ocular implants
US4853224A (en) 1987-12-22 1989-08-01 Visionex Biodegradable ocular implants
EP0356399A3 (en) 1988-08-26 1991-03-20 Sandoz Ag Substituted 4-azatricyclo (22.3.1.04.9) octacos-18-ene derivatives, their preparation and pharmaceutical compositions containing them
US4946450A (en) 1989-04-18 1990-08-07 Biosource Genetics Corporation Glucan/collagen therapeutic eye shields
US5100899A (en) 1989-06-06 1992-03-31 Roy Calne Methods of inhibiting transplant rejection in mammals using rapamycin and derivatives and prodrugs thereof
US5164188A (en) 1989-11-22 1992-11-17 Visionex, Inc. Biodegradable ocular implants
US5883082A (en) 1990-08-14 1999-03-16 Isis Pharmaceuticals, Inc. Compositions and methods for preventing and treating allograft rejection
US5192773A (en) 1990-07-02 1993-03-09 Vertex Pharmaceuticals, Inc. Immunosuppressive compounds
JPH04230389A (en) 1990-07-16 1992-08-19 American Home Prod Corp Rapamycin derivative
DE4022553A1 (en) 1990-07-16 1992-01-23 Hund Helmut Gmbh Medical contact lens - with recess contg. therapeutically or diagnostically active substance
US5023262A (en) 1990-08-14 1991-06-11 American Home Products Corporation Hydrogenated rapamycin derivatives
PT98990A (en) 1990-09-19 1992-08-31 American Home Prod PROCESS FOR THE PREPARATION OF CARBOXYLIC ACID ESTERS OF RAPAMICIN
US5290892A (en) 1990-11-07 1994-03-01 Nestle S.A. Flexible intraocular lenses made from high refractive index polymers
IE65341B1 (en) 1990-11-08 1995-10-18 Fujisawa Pharmaceutical Co Suspensions containing tricyclic compounds
US5378475A (en) 1991-02-21 1995-01-03 University Of Kentucky Research Foundation Sustained release drug delivery devices
US5078999A (en) 1991-02-22 1992-01-07 American Home Products Corporation Method of treating systemic lupus erythematosus
US5120842A (en) 1991-04-01 1992-06-09 American Home Products Corporation Silyl ethers of rapamycin
JP3158437B2 (en) 1991-04-26 2001-04-23 藤沢薬品工業株式会社 Use of macrolide compounds for eye diseases
US5565560A (en) 1991-05-13 1996-10-15 Merck & Co., Inc. O-Aryl,O-alkyl,O-alkenyl and O-alkynylmacrolides having immunosuppressive activity
US5120727A (en) 1991-05-29 1992-06-09 American Home Products Corporation Rapamycin dimers
US5120725A (en) 1991-05-29 1992-06-09 American Home Products Corporation Bicyclic rapamycins
IL102414A (en) 1991-07-25 1996-08-04 Univ Louisville Res Found Pharmaceutical compositions for treating ocular inflammation comprising rapamycin
US5189042A (en) 1991-08-22 1993-02-23 Merck & Co. Inc. Fluoromacrolides having immunosuppressive activity
US5457111A (en) 1991-09-05 1995-10-10 Abbott Laboratories Macrocyclic immunomodulators
US5192802A (en) 1991-09-25 1993-03-09 Mcneil-Ppc, Inc. Bioadhesive pharmaceutical carrier
US5679666A (en) 1991-11-22 1997-10-21 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids
US5770592A (en) 1991-11-22 1998-06-23 Alcon Laboratories, Inc. Prevention and treatment of ocular neovascularization using angiostatic steroids
US5516781A (en) 1992-01-09 1996-05-14 American Home Products Corporation Method of treating restenosis with rapamycin
US5177203A (en) 1992-03-05 1993-01-05 American Home Products Corporation Rapamycin 42-sulfonates and 42-(N-carboalkoxy) sulfamates useful as immunosuppressive agents
SG49652A1 (en) 1992-03-30 1998-06-15 American Home Prod Rapamycin formulation for iv injection
US5178635A (en) 1992-05-04 1993-01-12 Allergan, Inc. Method for determining amount of medication in an implantable device
FR2690846B1 (en) 1992-05-05 1995-07-07 Aiache Jean Marc GALENIC FORM FOR EYE ADMINISTRATION AND METHOD OF PREPARATION.
WO1994005257A1 (en) 1992-09-08 1994-03-17 Allergan, Inc. Sustained release of ophthalmic drugs from a soluble polymer drug delivery vehicle
GB9221220D0 (en) 1992-10-09 1992-11-25 Sandoz Ag Organic componds
US5258389A (en) 1992-11-09 1993-11-02 Merck & Co., Inc. O-aryl, O-alkyl, O-alkenyl and O-alkynylrapamycin derivatives
JP3520517B2 (en) 1992-11-18 2004-04-19 藤沢薬品工業株式会社 Sustained pharmaceutical preparations
EP0689545A4 (en) 1993-03-17 1996-04-24 Abbott Lab Macrocyclic amide and urea immunomodulators
GB2278780B (en) 1993-05-27 1998-10-14 Sandoz Ltd Macrolide formulations
US5798355A (en) 1995-06-07 1998-08-25 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity
EP2226085B1 (en) 1993-07-19 2013-11-27 Angiotech Pharmaceuticals, Inc. Anti-angiogenic compositions and methods of use
WO1995003009A1 (en) 1993-07-22 1995-02-02 Oculex Pharmaceuticals, Inc. Method of treatment of macular degeneration
US5616588A (en) 1993-09-30 1997-04-01 American Home Products Corporation Rapamycin formulation for IV injection
AU688782B2 (en) * 1993-09-30 1998-03-19 Wyeth Rapamycin formulations for oral administration
US5536729A (en) * 1993-09-30 1996-07-16 American Home Products Corporation Rapamycin formulations for oral administration
IL111004A (en) 1993-09-30 1998-06-15 American Home Prod Oral rapamycin formulations
US5516770A (en) 1993-09-30 1996-05-14 American Home Products Corporation Rapamycin formulation for IV injection
US5443505A (en) 1993-11-15 1995-08-22 Oculex Pharmaceuticals, Inc. Biocompatible ocular implants
EP0729471A1 (en) 1993-11-19 1996-09-04 Abbott Laboratories Semisynthetic analogs of rapamycin (macrolides) being immunomodulators
US5527907A (en) 1993-11-19 1996-06-18 Abbott Laboratories Macrolide immunomodulators
DE69423781T2 (en) 1993-12-17 2000-08-10 Novartis Ag RAPAMYCIN DERIVATIVES AS IMMUNO SUPPRESSORS
US5788687A (en) 1994-02-01 1998-08-04 Caphco, Inc Compositions and devices for controlled release of active ingredients
US5773021A (en) 1994-03-14 1998-06-30 Vetoquinol S.A. Bioadhesive ophthalmic insert
US5516522A (en) 1994-03-14 1996-05-14 Board Of Supervisors Of Louisiana State University Biodegradable porous device for long-term drug delivery with constant rate release and method of making the same
EP0754046A1 (en) 1994-04-04 1997-01-22 FREEMAN, William R. Use of phosphonylmethoxyalkyl nucleosides for the treatment of raised intraocular pressure
US5466233A (en) 1994-04-25 1995-11-14 Escalon Ophthalmics, Inc. Tack for intraocular drug delivery and method for inserting and removing same
US5621108A (en) 1994-12-05 1997-04-15 Trustees Of The University Of Pennsylvania Processes and intermediates for preparing macrocycles
US5725493A (en) 1994-12-12 1998-03-10 Avery; Robert Logan Intravitreal medicine delivery
JPH08333257A (en) * 1995-04-04 1996-12-17 Otsuka Pharmaceut Co Ltd Product holding pharmaceutical preparation of procaterol hydrochloride aqueous solution and pharmaceutical preparation of aqueous solution of procaterol hydrochloride
AU5857396A (en) 1995-05-14 1996-11-29 Optonol Ltd. Intraocular implant, delivery device, and method of implanta tion
US5696135A (en) 1995-06-07 1997-12-09 Gpi Nil Holdings, Inc. Inhibitors of rotamase enzyme activity effective at stimulating neuronal growth
WO1996041865A1 (en) 1995-06-07 1996-12-27 Ariad Gene Therapeutics, Inc. Rapamcycin-based regulation of biological events
US5614547A (en) 1995-06-07 1997-03-25 Guilford Pharmaceuticals Inc. Small molecule inhibitors of rotamase enzyme
US6037370A (en) 1995-06-08 2000-03-14 Vertex Pharmaceuticals Incorporated Methods and compositions for stimulating neurite growth
BE1009856A5 (en) 1995-07-14 1997-10-07 Sandoz Sa Pharmaceutical composition in the form of a solid release including macrolide and a vehicle.
JP3266005B2 (en) 1995-09-19 2002-03-18 藤沢薬品工業株式会社 Aerosol formulation and method for producing the same
US5773019A (en) 1995-09-27 1998-06-30 The University Of Kentucky Research Foundation Implantable controlled release device to deliver drugs directly to an internal portion of the body
WO1997016068A1 (en) 1995-10-31 1997-05-09 Merck & Co., Inc. Triterpene derivatives with immunosuppressant activity
GB9601120D0 (en) 1996-01-19 1996-03-20 Sandoz Ltd Organic compounds
EP0880362B1 (en) 1996-02-13 2005-05-25 G.D. SEARLE & CO. Compositions comprising a cyclooxygenase-2 inhibitor and a leukotriene b 4 receptor antagonist
US5743274A (en) 1996-03-18 1998-04-28 Peyman; Gholam A. Macular bandage for use in the treatment of subretinal neovascular members
US5904144A (en) 1996-03-22 1999-05-18 Cytotherapeutics, Inc. Method for treating ophthalmic diseases
JP3309175B2 (en) 1996-03-25 2002-07-29 参天製薬株式会社 Scleral plug containing proteinaceous drug
GB9710962D0 (en) 1997-05-28 1997-07-23 Univ Cambridge Tech Polyketides and their synthesis
RU2123314C1 (en) 1996-06-27 1998-12-20 Павлова Татьяна Вячеславовна Method of placing irrigation system into tenon's space
SI1208847T1 (en) 1996-07-30 2007-06-30 Novartis Ag Pharmaceutical compositions for the treatment of transplant rejection, as well as autoimmune or inflammatory conditions
US6142969A (en) 1996-10-25 2000-11-07 Anamed, Inc. Sutureless implantable device and method for treatment of glaucoma
US6007510A (en) 1996-10-25 1999-12-28 Anamed, Inc. Implantable devices and methods for controlling the flow of fluids within the body
AUPO427196A0 (en) 1996-12-19 1997-01-23 University Of Sydney, The A method for preventing or controlling cataract
TW450810B (en) 1997-02-20 2001-08-21 Fujisawa Pharmaceutical Co Macrolides antibiotic pharmaceutical composition for preventing and treating skin diseases
US6273913B1 (en) 1997-04-18 2001-08-14 Cordis Corporation Modified stent useful for delivery of drugs along stent strut
EP1003569B1 (en) 1997-08-11 2004-10-20 Allergan, Inc. Sterile bioerodible implant device containing retinoid with improved biocompatability and method of manufacture
US5902598A (en) 1997-08-28 1999-05-11 Control Delivery Systems, Inc. Sustained release drug delivery devices
US6342507B1 (en) 1997-09-05 2002-01-29 Isotechnika, Inc. Deuterated rapamycin compounds, method and uses thereof
US20060198867A1 (en) 1997-09-25 2006-09-07 Abbott Laboratories, Inc. Compositions and methods of administering rapamycin analogs using medical devices for long-term efficacy
US6890546B2 (en) 1998-09-24 2005-05-10 Abbott Laboratories Medical devices containing rapamycin analogs
US6015815A (en) 1997-09-26 2000-01-18 Abbott Laboratories Tetrazole-containing rapamycin analogs with shortened half-lives
US20030190286A1 (en) 1997-10-01 2003-10-09 Dugger Harry A. Buccal, polar and non-polar spray or capsule containing drugs for treating allergies or asthma
GB9721497D0 (en) * 1997-10-09 1997-12-10 Ciba Geigy Ag Organic compounds
IL135774A0 (en) 1997-10-22 2001-05-20 Ponikau Jens Use of antinfungal agents for the topical treatment of fungus-induced mucositis
ZA989885B (en) 1997-10-31 1999-05-05 Abbott Lab Use of macrolides for the treatment of cancer and macular degeneration
CZ287497B6 (en) 1997-12-30 2000-12-13 Galena, A. S. Topic eye preparations containing immunosuppressive substances
AU2337599A (en) 1998-01-23 1999-08-09 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
DE19810655A1 (en) 1998-03-12 1999-09-16 Univ Eberhard Karls Pharmaceutical composition containing cyclosporin A suitable for topical administration for treating disorders of skin, mucosa and eyes
JP2002506028A (en) 1998-03-13 2002-02-26 ジョンズ ホプキンズ ユニヴァーシティ スクール オヴ メディシン Use of a protein tyrosine inhibitor such as genistein in the treatment of diabetic retinopathy or ocular inflammation
EP1083896A4 (en) 1998-05-11 2002-09-11 Endowment For Res In Human Bio Use of neomycin for treating angiogenesis-related diseases
US6399629B1 (en) 1998-06-01 2002-06-04 Microcide Pharmaceuticals, Inc. Efflux pump inhibitors
US6378526B1 (en) 1998-08-03 2002-04-30 Insite Vision, Incorporated Methods of ophthalmic administration
US6376517B1 (en) 1998-08-14 2002-04-23 Gpi Nil Holdings, Inc. Pipecolic acid derivatives for vision and memory disorders
US7338976B1 (en) 1998-08-14 2008-03-04 Gpi Nil Holdings, Inc. Heterocyclic esters or amides for vision and memory disorders
US6384056B1 (en) 1998-08-14 2002-05-07 Gpi Nil Holdings, Inc. Heterocyclic thioesters or ketones for vision and memory disorders
US6632836B1 (en) 1998-10-30 2003-10-14 Merck & Co., Inc. Carbocyclic potassium channel inhibitors
US6303637B1 (en) 1998-10-30 2001-10-16 Merck & Co., Inc. Heterocyclic potassium channel inhibitors
US6472370B1 (en) 1998-11-17 2002-10-29 Ortho-Mcneil Pharmaceutical, Inc. Anticonvulsant derivatives useful in treating post traumatic stress disorder
US6399655B1 (en) 1998-12-22 2002-06-04 Johns Hopkins University, School Of Medicine Method for the prophylactic treatment of cataracts
EA005815B1 (en) 1998-12-23 2005-06-30 Джи.Ди.Сирл Ллс Combinations od ileal bile acid transport inhibitors and cholesteryl transfer protein inhibitors for cardiovascular indications
EP1140134A1 (en) 1998-12-24 2001-10-10 R-Tech Ueno, Ltd. Agent for treating visual cell function disorder
US6864232B1 (en) 1998-12-24 2005-03-08 Sucampo Ag Agent for treating visual cell function disorder
EP1154691A4 (en) 1999-01-05 2004-07-07 Massachusetts Eye & Ear Infirm Targeted transscleral controlled release drug delivery to the retina and choroid
US6706283B1 (en) 1999-02-10 2004-03-16 Pfizer Inc Controlled release by extrusion of solid amorphous dispersions of drugs
US7374779B2 (en) 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
US6267985B1 (en) 1999-06-30 2001-07-31 Lipocine Inc. Clear oil-containing pharmaceutical compositions
US6217895B1 (en) 1999-03-22 2001-04-17 Control Delivery Systems Method for treating and/or preventing retinal diseases with sustained release corticosteroids
US6239113B1 (en) 1999-03-31 2001-05-29 Insite Vision, Incorporated Topical treatment or prevention of ocular infections
US6254860B1 (en) 1999-04-13 2001-07-03 Allergan Sales, Inc. Ocular treatment using cyclosporin-A derivatives
US7063857B1 (en) 1999-04-30 2006-06-20 Sucampo Ag Use of macrolide compounds for the treatment of dry eye
EP1173177B2 (en) 1999-04-30 2014-03-05 Sucampo AG Use of macrolide compounds for the treatment of dry eye
US6576224B1 (en) 1999-07-06 2003-06-10 Sinuspharma, Inc. Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
JP2001064198A (en) 1999-08-24 2001-03-13 Teika Seiyaku Kk Therapeutic agent for corneal disease
CN1292721C (en) 1999-10-21 2007-01-03 爱尔康公司 Drug delivery device
PT1221918E (en) 1999-10-21 2005-06-30 Alcon Inc ADMINISTRATION OF SUB-TENON DRUGS
US6416777B1 (en) 1999-10-21 2002-07-09 Alcon Universal Ltd. Ophthalmic drug delivery device
ATE383873T1 (en) 1999-10-22 2008-02-15 Biogen Idec Inc USE OF A CD40:CD154 LINKAGE DISRUPTER FOR THE TREATMENT OF IMMUNOLOGICAL EYE COMPLICATIONS
US6331313B1 (en) 1999-10-22 2001-12-18 Oculex Pharmaceticals, Inc. Controlled-release biocompatible ocular drug delivery implant devices and methods
WO2001030337A2 (en) 1999-10-22 2001-05-03 Orbon Corporation Ophthalmic formulation of dopamine antagonists
ES2283344T3 (en) 1999-10-29 2007-11-01 Kosan Biosciences, Inc. RAPAMYCIN ANALOGS.
RU2149615C1 (en) 1999-11-10 2000-05-27 Нестеров Аркадий Павлович Method for introducing drugs in treating posterior eye segment diseases
US6531464B1 (en) 1999-12-07 2003-03-11 Inotek Pharmaceutical Corporation Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives
AU784340B2 (en) 1999-12-23 2006-03-16 Pfizer Products Inc. Pharmaceutical compositions providing enhanced drug concentrations
US6489335B2 (en) 2000-02-18 2002-12-03 Gholam A. Peyman Treatment of ocular disease
US20030018044A1 (en) 2000-02-18 2003-01-23 Peyman Gholam A. Treatment of ocular disease
DE60100866T2 (en) 2000-04-07 2004-07-29 Laboratoire Medidom S.A. Ophthalmic medicinal product containing cyclosporine, hyaluronic acid and polysorbate
US6375972B1 (en) 2000-04-26 2002-04-23 Control Delivery Systems, Inc. Sustained release drug delivery devices, methods of use, and methods of manufacturing thereof
CN1127955C (en) 2000-07-07 2003-11-19 中山医科大学中山眼科中心 Medicine for treating immune relative disease of anterior chamber and surface of eye
CN1204919C (en) 2000-08-30 2005-06-08 中国科学院化学研究所 Long-acting intra-ocular release system of cyclosporin
ES2312456T3 (en) 2000-08-30 2009-03-01 Johns Hopkins University DEVICES FOR INTRAOCULAR SUPPLY OF PHARMACOS.
US6696483B2 (en) 2000-10-03 2004-02-24 Oncopharmaceutical, Inc. Inhibitors of angiogenesis and tumor growth for local and systemic administration
US6534693B2 (en) 2000-11-06 2003-03-18 Afmedica, Inc. Surgically implanted devices having reduced scar tissue formation
US20050084514A1 (en) 2000-11-06 2005-04-21 Afmedica, Inc. Combination drug therapy for reducing scar tissue formation
US20040018228A1 (en) 2000-11-06 2004-01-29 Afmedica, Inc. Compositions and methods for reducing scar tissue formation
DE60114229T2 (en) 2000-11-29 2006-07-06 Allergan, Inc., Irvine PREVENTING TRANSPLANT DISCHARGE IN THE EYE
CA2433032C (en) 2001-01-03 2008-11-25 Bausch & Lomb Incorporated Sustained release drug delivery devices with coated drug cores
AP2003002828A0 (en) 2001-01-16 2003-09-30 Vascular Therapies Llc Implantable device containing resorbable matrix material and anti-proliferative drugs for preventing or treating failure of hemodialysis vascular access and other vascular grafts.
US7181287B2 (en) 2001-02-13 2007-02-20 Second Sight Medical Products, Inc. Implantable drug delivery device
EP3406249A1 (en) 2001-02-19 2018-11-28 Novartis AG Treatment of breast tumors with a rapamycin derivative in combination with an aromatase inhibitor
US6777000B2 (en) 2001-02-28 2004-08-17 Carrington Laboratories, Inc. In-situ gel formation of pectin
US6713081B2 (en) 2001-03-15 2004-03-30 The United States Of America As Represented By The Department Of Health And Human Services Ocular therapeutic agent delivery devices and methods for making and using such devices
AR033151A1 (en) 2001-04-12 2003-12-03 Sucampo Pharmaceuticals Inc AGENT FOR THE TOPICAL OPHTHALMIC TREATMENT OF OCULAR INFLAMMATORY DISEASES
WO2002089767A1 (en) 2001-05-03 2002-11-14 Massachusetts Eye And Ear Infirmary Implantable drug delivery device and use thereof
EP2316394B1 (en) 2001-06-12 2016-11-23 The Johns Hopkins University Reservoir device for intraocular drug delivery
US7034037B2 (en) 2001-06-29 2006-04-25 Ethicon, Inc. Compositions and medical devices utilizing bioabsorbable polymeric waxes and rapamycin
CA2452372A1 (en) 2001-07-06 2003-01-16 Sucampo Ag Composition for topical administration comprising an interleukin-2 inhibitor and an antimicrobial agent
AR035293A1 (en) 2001-08-23 2004-05-05 Novartis Ag OPHTHALMIC COMPOSITION.
US6812220B2 (en) 2001-08-29 2004-11-02 University Of British Columbia Pharmaceutical compositions and methods relating to fucans
GB0122318D0 (en) 2001-09-14 2001-11-07 Novartis Ag Organic compounds
JP2003113078A (en) 2001-09-28 2003-04-18 Lion Corp Ophthalmic preparation
US6656460B2 (en) 2001-11-01 2003-12-02 Yissum Research Development Method and composition for dry eye treatment
US6939376B2 (en) 2001-11-05 2005-09-06 Sun Biomedical, Ltd. Drug-delivery endovascular stent and method for treating restenosis
EP1441743A4 (en) 2001-11-09 2009-02-25 Eyetech Pharmaceuticals Methods for treating ocular neovascular diseases
US6663880B1 (en) 2001-11-30 2003-12-16 Advanced Cardiovascular Systems, Inc. Permeabilizing reagents to increase drug delivery and a method of local delivery
EP1455810B1 (en) 2001-12-14 2007-06-13 Jagotec Ag Pharmaceutical formulation comprising cyclosporin and use thereof
GB0200429D0 (en) 2002-01-09 2002-02-27 Novartis Ag Organic compounds
CA2478424A1 (en) 2002-03-01 2003-09-12 Novagali Pharma Sa Self emulsifying drug delivery systems for poorly soluble drugs
JP2003261449A (en) * 2002-03-05 2003-09-16 Nisshin Oillio Ltd Famotidine-containing aqueous injection preparation and method for producing the same
US6941948B2 (en) 2002-03-07 2005-09-13 Vectura Drug Delivery Medicament storage and delivery devices
CN1456350A (en) 2002-05-10 2003-11-19 刘继东 Eye cyclosporin gel
US20040057958A1 (en) 2002-05-17 2004-03-25 Waggoner David W. Immunogenicity-enhancing carriers and compositions thereof and methods of using the same
US7026374B2 (en) 2002-06-25 2006-04-11 Aruna Nathan Injectable microdispersions for medical applications
EP2277898A3 (en) 2002-07-16 2011-06-01 Biotica Technology Limited Rapamycin analogues
AU2003256068A1 (en) 2002-08-09 2004-02-25 Sucampo Pharmaceuticals, Inc. Pharmaceutical compositions comprising fk506 derivatives and the ir use for the treatment of allergic diseases
WO2004027027A2 (en) 2002-09-18 2004-04-01 Trustees Of The University Of Pennsylvania Method of inhibiting choroidal neovascularization
AU2003279055A1 (en) 2002-09-29 2004-04-19 Surmodics, Inc. Methods for treatment and/or prevention of retinal disease
US7704518B2 (en) 2003-08-04 2010-04-27 Foamix, Ltd. Foamable vehicle and pharmaceutical compositions thereof
US7354574B2 (en) 2002-11-07 2008-04-08 Advanced Ocular Systems Limited Treatment of ocular disease
AU2003293529A1 (en) 2002-12-16 2004-07-29 Nitromed, Inc. Nitrosated and nitrosylated rapamycin compounds, compositions and methods of use
AR042890A1 (en) 2003-01-16 2005-07-06 Sucampo Pharmaceuticals Inc METHOD OF DRY EYE TREATMENT WITH AN OPHTHALMIC COMPOSITION CONTAINING A MACROLID COMPOUND
CA2516022C (en) 2003-02-17 2012-05-29 Cold Spring Harbor Laboratory Model for studying the role of genes in tumor resistance to chemotherapy
JP2004269419A (en) * 2003-03-07 2004-09-30 Mochida Pharmaceut Co Ltd Aqueous injection containing miconazole
US20050074497A1 (en) 2003-04-09 2005-04-07 Schultz Clyde L. Hydrogels used to deliver medicaments to the eye for the treatment of posterior segment diseases
US20050255144A1 (en) 2003-04-09 2005-11-17 Directcontact Llc Methods and articles for the delivery of medicaments to the eye for the treatment of posterior segment diseases
WO2004096261A1 (en) 2003-05-02 2004-11-11 Arturo Jimenez Bayardo Method of preparing an aqueous solution of cyclosporin-a and resulting aqueous solution
US7160867B2 (en) 2003-05-16 2007-01-09 Isotechnika, Inc. Rapamycin carbohydrate derivatives
US7674170B2 (en) 2003-06-25 2010-03-09 Odom James M Method of lottery wagering on a real world phased competition
EP1635875B8 (en) 2003-06-26 2008-12-24 pSivida Inc In-situ gelling drug delivery system
US7083802B2 (en) 2003-07-31 2006-08-01 Advanced Ocular Systems Limited Treatment of ocular disease
US20050037048A1 (en) * 2003-08-11 2005-02-17 Young-Ho Song Medical devices containing antioxidant and therapeutic agent
EP1510206A1 (en) 2003-08-29 2005-03-02 Novagali Pharma SA Self-nanoemulsifying oily formulation for the administration of poorly water-soluble drugs
US7585517B2 (en) 2003-09-18 2009-09-08 Macusight, Inc. Transscleral delivery
US20050181018A1 (en) 2003-09-19 2005-08-18 Peyman Gholam A. Ocular drug delivery
US7087237B2 (en) 2003-09-19 2006-08-08 Advanced Ocular Systems Limited Ocular solutions
US7083803B2 (en) 2003-09-19 2006-08-01 Advanced Ocular Systems Limited Ocular solutions
US7402399B2 (en) 2003-10-14 2008-07-22 Monogram Biosciences, Inc. Receptor tyrosine kinase signaling pathway analysis for diagnosis and therapy
WO2005051451A2 (en) 2003-11-20 2005-06-09 Angiotech International Ag Electrical devices and anti-scarring agents
WO2005051316A2 (en) 2003-11-20 2005-06-09 Angiotech International Ag Polymer compositions and methods for their use
WO2006053007A2 (en) 2004-11-09 2006-05-18 Angiotech Biocoatings Corp. Antimicrobial needle coating for extended infusion
US7186518B2 (en) 2003-11-21 2007-03-06 Dade Behring Inc. Method and composition useful for determining FK 506
AU2004296851A1 (en) 2003-12-08 2005-06-23 Gel-Del Technologies, Inc. Mucoadhesive drug delivery devices and methods of making and using thereof
US20050256081A1 (en) 2004-02-26 2005-11-17 Peyman Gholam A Tetracycline derivatives for the treatment of ocular pathologies
WO2005094279A2 (en) 2004-03-25 2005-10-13 The Rothberg Institute For Childhood Diseases Immortalized human tuberous sclerosis null angiomyolipoma cell and method of use thereof
US7846940B2 (en) 2004-03-31 2010-12-07 Cordis Corporation Solution formulations of sirolimus and its analogs for CAD treatment
US20050245497A1 (en) 2004-04-08 2005-11-03 Penfold Philip L Treatment of ophthalmic conditions
US20050244472A1 (en) 2004-04-30 2005-11-03 Allergan, Inc. Intraocular drug delivery systems containing excipients with reduced toxicity and related methods
US20060182783A1 (en) 2004-04-30 2006-08-17 Allergan, Inc. Sustained release intraocular drug delivery systems
US20050250804A1 (en) 2004-05-06 2005-11-10 Glenmark Pharmaceuticals Limited Pharmaceutical gel formulations
US20060024350A1 (en) 2004-06-24 2006-02-02 Varner Signe E Biodegradable ocular devices, methods and systems
US20060018948A1 (en) 2004-06-24 2006-01-26 Guire Patrick E Biodegradable implantable medical devices, methods and systems
WO2006002365A2 (en) 2004-06-24 2006-01-05 Angiotech International Ag Microparticles with high loadings of a bioactive agent
JP2008512350A (en) 2004-07-01 2008-04-24 イェール ユニバーシティ Polymeric substances that are targeted and loaded with drugs at high density
WO2006014484A2 (en) 2004-07-02 2006-02-09 Surmodics, Inc. Methods and devices for the treatment of ocular conditions
WO2006020755A2 (en) 2004-08-10 2006-02-23 Beth Israel Deaconess Medical Center, Inc. Methods for identifying inhibitors of the mtor pathway as diabetes therapeutics
WO2006023130A2 (en) 2004-08-12 2006-03-02 Surmodics, Inc. Biodegradable controlled release bioactive agent delivery device
AR050374A1 (en) 2004-08-20 2006-10-18 Wyeth Corp RAFAMPICINE POLYMORPHIC FORM
EP3173072A1 (en) 2004-10-01 2017-05-31 Ramscor, Inc. Conveniently implantable sustained release drug compositions
MX2007003789A (en) 2004-10-04 2007-07-20 Qlt Usa Inc Ocular delivery of polymeric delivery formulations.
GB0504995D0 (en) 2005-03-11 2005-04-20 Biotica Tech Ltd Use of a compound
JP2008533204A (en) 2005-03-21 2008-08-21 マクサイト， インコーポレイテッド Drug delivery system for treatment of disease or condition
US20060216288A1 (en) 2005-03-22 2006-09-28 Amgen Inc Combinations for the treatment of cancer
JP2008535847A (en) 2005-04-08 2008-09-04 サーモディクス，インコーポレイティド Sustained release implant for subretinal delivery
NZ563003A (en) 2005-04-27 2011-03-31 Univ Florida Use of a farnesyl transferase inhibitor to enhance autophagic protein degradation in protein conformation disorders
US20060247265A1 (en) 2005-04-28 2006-11-02 Clackson Timothy P Therapies for treating disorders of the eye
JP2009500297A (en) 2005-06-08 2009-01-08 セントカー・インコーポレーテツド Cell therapy for ocular degeneration
EP1904056B1 (en) 2005-07-18 2009-04-29 Minu, L.L.C. Use of a macrolide to restore corneal sensation
US20070014760A1 (en) 2005-07-18 2007-01-18 Peyman Gholam A Enhanced recovery following ocular surgery
US20070134244A1 (en) 2005-10-14 2007-06-14 Alcon, Inc. Combination treatment for pathologic ocular angiogenesis
JP5528708B2 (en) 2006-02-09 2014-06-25 参天製薬株式会社 Stable formulations and methods for preparing and using them
JP2009528381A (en) 2006-02-28 2009-08-06 パロマ ファーマシューティカルズ，インク． Compositions and methods for treating diseases characterized by cell proliferation and angiogenesis
CN101443004B (en) 2006-03-23 2013-03-06 参天制药株式会社 Formulations and methods for vascular permeability-related diseases or conditions

Patent Citations (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2382240A1 (en) * 1977-03-03 1978-09-29 Mouls Pierre Ophthalmic solution diffusion equipment - delivers fine mist to cornea indirectly using cup with baffles
WO2000006121A1 (en) * 1998-07-24 2000-02-10 Jago Research Ag Medicinal aerosol formulations
WO2000033878A2 (en) * 1998-12-07 2000-06-15 Novartis Ag Stabilization of macrolides
WO2001028522A2 (en) * 1999-10-18 2001-04-26 Fujisawa Pharmaceutical Co., Ltd. Method for producing liposome preparation
WO2001093830A1 (en) * 2000-06-06 2001-12-13 Pharmatop Scr Method for obtaining aqueous formulations of oxidation-sensitive active principles
JP2002332225A (en) * 2001-05-09 2002-11-22 Lion Corp Ophthalmic composition
WO2004011000A1 (en) * 2002-07-30 2004-02-05 Wyeth Parenteral formulations containing a rapamycin hydroxyester
WO2006026531A1 (en) * 2004-08-27 2006-03-09 Cordis Corporation Solvent free amorphous rapamycin
WO2006086750A1 (en) * 2005-02-09 2006-08-17 Macusight, Inc. Liquid formulations for treatment of diseases or conditions
WO2007065588A1 (en) * 2005-12-06 2007-06-14 Pari Pharma Gmbh Pharmaceutical compositions comprising cyclosporin
WO2007083316A2 (en) * 2006-01-23 2007-07-26 Yissum Research Development Company Of The Hebrew University Of Jerusalem Microspheres comprising nanocapsules containing a lipophilic drug

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
DATABASE WPI Week 200314, Derwent World Patents Index; AN 2003-143412, XP002493864 *

Also Published As

Publication number Publication date
JP2009528276A (en) 2009-08-06
US8492400B2 (en) 2013-07-23
US20070203173A1 (en) 2007-08-30
CN101605529B (en) 2013-03-13
JP5528708B2 (en) 2014-06-25
US20140011834A1 (en) 2014-01-09
BRPI0707612B1 (en) 2020-09-24
US8658667B2 (en) 2014-02-25
WO2007092620A2 (en) 2007-08-16
BRPI0707612A2 (en) 2011-05-10
EP2001438A2 (en) 2008-12-17
KR20140093764A (en) 2014-07-28
AU2007212271A1 (en) 2007-08-16
AU2007212271B2 (en) 2012-11-01
KR101478164B1 (en) 2014-12-31
CN101605529A (en) 2009-12-16
BRPI0707612B8 (en) 2021-05-25
CA2635797C (en) 2015-03-31
CA2635797A1 (en) 2007-08-16
KR20080094814A (en) 2008-10-24

Similar Documents

Publication Publication Date Title
WO2007092620A3 (en) Stable formulations, and methods of their preparation and use
WO2006099169A3 (en) Novel liposome compositions
ZA200809864B (en) Pharmaceutical formulations for the sustained release of active ingredients(s), as well as their applications, especially therapeutic
MY143795A (en) Tetrahydropyridoindole derivatives
IL221770A (en) Adamantyl-acetamide derivatives, pharmaceutical compositions comprising same and use thereof for preparation of medicaments
CL2007002708A1 (en) COMPOUNDS DERIVED FROM PIRROLO [2,3-B] PIRIDINA; PREPARATION PROCEDURE; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS CANCER, CAQUEXY, INFLAMMATORY DISORDERS, AMONG OTHERS.
WO2007149406A3 (en) Modified coagulation factor ix polypeptides and use thereof for treatment
ATE470443T1 (en) INDOL-1-YL ACID DERIVATIVES
CL2007002513A1 (en) COMPOUNDS DERIVED FROM SUBSTITUTED ISOINDOLIN, INTERMEDIATE COMPOUNDS; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT AND PREVENTION OF DISEASES SUCH AS CANCER, PAIN, MACULAR DEGENERATION, AMONG OTHERS.
WO2005112633A3 (en) Compounds and compositions for delivering active agents
WO2012021715A3 (en) Stable formulations of linaclotide
WO2008087367A3 (en) Substituted (phenylthiazolyl)-phenyl-propan-1-one and (phenyloxazodyl)-phenyl-propan-1-one derivatives, preparations and uses of same
WO2010021607A3 (en) Pharmaceutical formulation
CL2011000119A1 (en) Compounds derived from triazolo [4,3-a] pyridine; preparation procedure; pharmaceutical composition; and use in the treatment of diseases such as cancer.
ZA200801575B (en) Pharmaceutical formulations/composition of guanfacine suitable for single dose form administration daily
WO2008023362A3 (en) Use of a combination of methotrexate and an a3ar agonist for the treatment of cancer
MX2009010165A (en) New imidazo[ 4,5-b]pyridine-7-carboxamides 704.
WO2011019326A3 (en) Solubility and stability enchancing pharmaceutical formulation
WO2009032843A3 (en) Deuterated ethambutols and their use
WO2012030914A8 (en) 4-azolylaminoquinazoline derivatives and methods of use thereof
WO2006076097A3 (en) Stable non-crystalline formulation comprising losartan
DK1869038T3 (en) Substituted 5,6,7,8-tetrahydro-imidazole [1,2-a] pyridin-2-ylamine compounds and their use in the manufacture of drugs
TW200626581A (en) Compounds, compositions containing them, preparation thereof and uses thereof
ZA201000581B (en) 1,2,3,4-tetrahydropyrrolo[1,2-a]pyrazine-6-carboxamide and 2,3,4,5-tetrahydropyrrolo[1,2-a][1,4]-diazepine-7-carboxamide derivatives,preparation and therapeutic use thereof
WO2008004100A9 (en) Therapeutic compounds

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 200780004951.4

Country of ref document: CN

WWE Wipo information: entry into national phase

Ref document number: 2007212271

Country of ref document: AU

WWE Wipo information: entry into national phase

Ref document number: 2635797

Country of ref document: CA

ENP Entry into the national phase

Ref document number: 2007212271

Country of ref document: AU

Date of ref document: 20070209

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: 3176/KOLNP/2008

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2008554395

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

WWE Wipo information: entry into national phase

Ref document number: 2007763361

Country of ref document: EP

ENP Entry into the national phase

Ref document number: PI0707612

Country of ref document: BR

Kind code of ref document: A2

Effective date: 20080811

WWE Wipo information: entry into national phase

Ref document number: 1020147020142

Country of ref document: KR